For the first time in Cuba, the patient will undergo a molecular and a clinical diagnosis for this disease.
Cuban President Miguel Díaz-Canel praised today the success of the COVID-19 pediatric immunization program launched in the country in preventing any decease among children and shared the results of a study by the Pedro Kourí Tropical Medicine Institute proving that, during the Omicron surge, the vaccine Soberana was 90.1% effective in the 2 to 5 age group and 95.8% in children between the ages of two and eighteen.
The president of Cuba, Miguel Diaz-Canel, alerted the authorities of the Ministry of Public Health (MINSAP) about the need to take measures to reinforce the population's perception of risk in the face of Covid-19.
The inclusion of patients in the NeuroEpo clinical trial (CT) in mild and moderate Alzheimer's will begin in Holguín next September, after a period of organization and evaluation in the territory, where the study will be assumed by the Provincial Group of CT and will include a multidisciplinary team of neurologists, psychiatrists, neuropsychologists, among other specialties.